ARMP Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Armata Pharmaceuticals's net margin of 12.11%. Armata Pharmaceuticals's return on equity of -- beat Electromed's return on equity of 15.91%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 438.46%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 64.88%. Given that Armata Pharmaceuticals has higher upside potential than Electromed, analysts believe Armata Pharmaceuticals is more attractive than Electromed.

Armata Pharmaceuticals has a beta of 0.907, which suggesting that the stock is 9.252% less volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Armata Pharmaceuticals's net income of $2.6M is higher than Electromed's net income of $2M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Electromed's PE ratio is 29.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 471.21x versus 3.37x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Innoviva has a net margin of -- compared to Armata Pharmaceuticals's net margin of -52.56%. Armata Pharmaceuticals's return on equity of -- beat Innoviva's return on equity of -8.85%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 438.46%. On the other hand Innoviva has an analysts' consensus of $55.00 which suggests that it could grow by 195.54%. Given that Armata Pharmaceuticals has higher upside potential than Innoviva, analysts believe Armata Pharmaceuticals is more attractive than Innoviva.

Armata Pharmaceuticals has a beta of 0.907, which suggesting that the stock is 9.252% less volatile than S&P 500. In comparison Innoviva has a beta of 0.353, suggesting its less volatile than the S&P 500 by 64.673%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Innoviva quarterly revenues of $88.6M. Armata Pharmaceuticals's net income of $2.6M is higher than Innoviva's net income of -$46.6M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Innoviva's PE ratio is 98.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 471.21x versus 3.72x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of -35.79%. Armata Pharmaceuticals's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 438.46%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 893.15%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

Armata Pharmaceuticals has a beta of 0.907, which suggesting that the stock is 9.252% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Armata Pharmaceuticals's net income of $2.6M is higher than Protalix BioTherapeutics's net income of -$3.6M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 36.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 471.21x versus 2.05x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Armata Pharmaceuticals's net margin of -10.04%. Armata Pharmaceuticals's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 438.46%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 236.54%. Given that Armata Pharmaceuticals has higher upside potential than Xtant Medical Holdings, analysts believe Armata Pharmaceuticals is more attractive than Xtant Medical Holdings.

Armata Pharmaceuticals has a beta of 0.907, which suggesting that the stock is 9.252% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Armata Pharmaceuticals's net income of $2.6M is higher than Xtant Medical Holdings's net income of -$3.2M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 471.21x versus 0.59x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.